CSF Aβ42 is the comparator biomarker discussed in the abstract. The paper argues that ratio-based measures perform better than Aβ42 alone for AD-related diagnostic tasks.
First-pass extracted concept
CSF Aβ42
Candidate: concept label1 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
What the tool is doing
What it does not solve
Evidence Snippets
Supporting Sources
Linked Claims
Decline in CSF Aβ42 is associated with non-AD subcortical pathologies.
Quoted textsource-backed
decline in CSF Aβ42 is also associated with non-AD subcortical pathologies
CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios should be used rather than CSF Aβ42 alone in the clinical work-up of Alzheimer disease.
Quoted textsource-backed
These findings strongly suggest that the ratios rather than CSF Aβ42 should be used in the clinical work-up of AD.
CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 alone for detecting brain amyloid deposition in prodromal Alzheimer disease.
Quoted textsource-backed
The CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 to detect brain amyloid deposition in prodromal AD
CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 alone for differentiating Alzheimer disease dementia from non-Alzheimer dementias.
Quoted textsource-backed
The CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 to ... differentiate AD dementia from non-AD dementias.
CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios reflect AD-type pathology better than CSF Aβ42 alone.
Quoted textsource-backed
The ratios reflect AD-type pathology better, whereas decline in CSF Aβ42 is also associated with non-AD subcortical pathologies.